
Johnson & Johnson has submitted an sNDA to the FDA for Caplyta for the treatment of bipolar mania.
Patients with bipolar disorder often find it difficult to maintain schedules and routines, all the more challenging with the COVID-19 pandemic. More in this video.
Patients with

